2024-06-26 13:45:17 ET
Summary
- Greenwich LifeSciences, Inc. is a late-stage biotech company focusing on developing an immunotherapy treatment for breast cancer.
- Their pipeline includes one drug, GLSI-100, currently in a phase 3 trial targeting breast cancer recurrence after surgery.
- Financially, Greenwich LifeSciences has limited resources with a cash runway of approximately 2 quarters, making it a high-risk investment.
Topline Summary
Read the full article on Seeking Alpha
For further details see:
Greenwich LifeSciences: Trying To Move A Needle That Doesn't Like To Budge